Public Health Industrial Base Capabilities and Capacities: Essential Medicines
Type: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSEASPR ADMINISTRATION FOR STRATEGIC PREPAREDNESS AND RESPONSEWashington, DC, 20201, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/701c75fc0a294fe9aa9b08543ce5c646/view
Timeline
    Description

    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (ASPR), is seeking information from industry partners regarding the domestic production capabilities and capacities related to essential medicines. This Request for Information (RFI) aims to gather data on the production of 28 specified essential medicines, including insights on manufacturing capacities, regulatory compliance, and supply chain challenges, as part of efforts to strengthen the public health industrial base in the U.S. The initiative reflects the government's commitment to ensuring readiness for public health emergencies by bolstering domestic pharmaceutical manufacturing. Interested parties should note that the clarifications due date is May 27, 2025, and the RFI submission deadline is June 9, 2025. For further inquiries, contact Lori Fischer at lori.fischer@hhs.gov or (202) 260-1679, or Roger Henriquez at IBMSC-Submissions@hhs.gov or (240) 581-4008.

    Files
    Title
    Posted
    Amendment 1 ASPR IBMSC RFI_Priority EMs.pdf
    The ASPR Industrial Base Management and Supply Chain has issued a Request for Information (RFI) focused on enhancing the understanding of the domestic production capabilities and capacities related to essential medicines as defined by Executive Orders 13944 and 14293. This RFI is part of efforts to bolster the public health industrial base (PHIB) in the U.S. and aims to solicit data regarding the production of vital drugs and biologics. Industry partners are invited to provide insights on their ability to produce and supply precursors, key starting materials, and finished dosage forms of 28 specified essential medicines, alongside details regarding regulatory compliance, manufacturing capacities, and supply chain challenges. The submission process allows for confidential trade secrets and emphasizes a structured format for responses, highlighting the government’s intent to use this information for planning rather than forming binding contracts. Ultimately, this initiative reflects the U.S. government’s commitment to reinforcing domestic pharmaceutical manufacturing to ensure readiness for public health emergencies.
    Lifecycle
    Title
    Type
    Public Health Industrial Base Capabilities and Capacities: Essential Medicines
    Currently viewing
    Special Notice
    Similar Opportunities
    COVID 19 Tests
    Buyer not available
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response, is seeking procurement for COVID-19 tests. The opportunity involves the acquisition of in vitro diagnostic substances, reagents, test kits, and sets, with a focus on ensuring compliance with the Trade Agreements Act (TAA). This procurement is critical for enhancing the nation's testing capabilities in response to the ongoing pandemic. Interested vendors can reach out to Junli Collins at junli.collins@hhs.gov or Judy Williams at judy.williams2@hhs.gov for further details, as outlined in the attached justification document.
    Health Care Delivery Solutions (HCDS) Electronic Health Record Follow-on (MHS GENESIS)
    Buyer not available
    The Department of Defense, through the Defense Health Agency (DHA), is seeking industry input for the Health Care Delivery Solutions (HCDS) Electronic Health Record (EHR) Follow-on (MHS GENESIS) procurement. This initiative aims to modernize the DoD's healthcare management system by enhancing interoperability, optimizing patient care, and leveraging commercial technology advancements while ensuring efficient integration with the Department of Veterans Affairs (VA). The procurement process is critical for maintaining a robust electronic health record system that serves approximately 9.6 million beneficiaries and 194,000 users. Interested parties are encouraged to submit their responses to the Request for Information (RFI) by November 17, 2025, and can direct inquiries to Sonya Edom at sonya.m.edom.civ@health.mil or Gabriela Hurte at gabriela.y.hurte.civ@health.mil. The anticipated timeline includes a draft RFP in Q1 FY26 and contract awards by Q4 FY26.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense (DoD) is soliciting quotes for pharmaceutical agents as part of its Uniform Formulary Blanket Purchase Agreement (UF BPA) and Uniform Formulary Additional Discount Program (UF ADP) through the Defense Health Agency (DHA). This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on the clinical and cost-effectiveness of drugs to determine their classification within the formulary. The P&T Committee will review newly approved drugs, including agents for pulmonary, gynecological, endocrine, atopy, skeletal muscle relaxants, and pain management, with quotes due by December 9, 2025, ahead of the committee meeting scheduled for February 4-5, 2026. Interested manufacturers should contact Stephanie Erpelding or Tracy Banks for further details and ensure compliance with submission requirements outlined in the RFQ HT9402-26-Q-9102.
    Resilient Systems Office (RSO) Mission Office Innovative Solutions Opening (ISO)
    Buyer not available
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Resilient Systems Office (RSO) Mission Office Innovative Solutions Opening (ISO). This opportunity invites submissions that address systemic challenges in healthcare and public health by leveraging innovative technologies to improve care quality, efficacy, and accessibility. Proposals will be evaluated based on scientific merit, alignment with ARPA-H's mission, proposer capabilities, and cost, with a focus on open-source intellectual property and compliance with research regulations. Interested parties must submit solution summaries and proposals via the designated ARPA-H portal, with the closing date for submissions set for March 5, 2029. For further inquiries, proposers can reach out through the same portal.
    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
    Buyer not available
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Broad Agency Announcement (BAA) BAA-23-100-SOL-00004 for advanced research and development of Medical Countermeasures (MCMs) targeting chemical, biological, radiological, nuclear threats, and emerging infectious diseases, including pandemic influenza. The initiative aims to enhance public health preparedness by fostering partnerships with private organizations, government laboratories, and academic institutions to expedite the development of life-saving MCMs critical for national health security. Proposals will be evaluated based on scientific merit, technological maturity, and regulatory compliance, with an open submission period running until September 25, 2028, at 4:30 PM Eastern Time. Interested parties should direct inquiries to BARDA-BAA@hhs.gov for further information.
    Assay Development for Superior Understanding of Response and Efficacy (ASSURE)
    Buyer not available
    The Department of Health and Human Services, through the Office of Assistant Secretary for Preparedness and Response (ASPR BARDA), is soliciting proposals for the ASSURE program, which focuses on the development of innovative assays to evaluate immune responses to infections and vaccinations. The primary objective is to create multiplexed, high-throughput, scalable, and sample-sparing assays that can assess immune status in response to chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and other emerging infectious diseases. Approximately $8 million is available for four to five awards, with proposals evaluated based on technical approach, relevant experience, and cost reasonableness. Interested parties must submit an abstract by December 18, 2025, and can contact Rebecca Harmon at rebecca.harmon@ati.org or 843.760.3358 for further information.
    Online Database of Preventive and Travel Health Information-Enterprise and Aerial Route Intelligence Subscription Services-Request for Information
    Buyer not available
    The Department of Homeland Security (DHS), Office of Health Security (OHS), is seeking qualified vendors to provide an enterprise-level online database and alert service for preventive and travel health information, as part of a Request for Information (RFI). The objective is to enhance DHS workforce health readiness and epidemiological monitoring through a subscription service that includes features such as aerial route risk mapping, continuous updates on infectious diseases, vaccination requirements, and access to medical facilities. This service is critical for ensuring timely, evidence-based information for risk assessment and travel planning for up to 1,000 users, thereby supporting the health and safety of DHS personnel. Interested parties must submit their capability statements by December 10, 2025, and can contact Mark Namoco at mark.namoco@hq.dhs.gov or Brendan Benisek at Brendan.Benisek@hq.dhs.gov for further information.
    FY26 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
    Buyer not available
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is soliciting proposals through the FY26 Broad Agency Announcement (BAA) for advanced research and development in regulatory science. This opportunity aims to acquire basic and applied research that supports regulatory science and innovation, focusing on areas such as New Approach Methodologies, Advanced Manufacturing, and Clinical Outcome Assessments, among others. The FDA's initiative is crucial for enhancing scientific knowledge that aids in protecting and promoting public health, particularly for underrepresented populations and in reducing animal testing. Interested parties, including small businesses and academic institutions, are encouraged to submit proposals by February 24, 2026, and can reach out to Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.
    Medication - Phenburane
    Buyer not available
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for the procurement of Phenburane, a medication classified under pharmaceutical preparation manufacturing. This solicitation aims to acquire a specific drug that plays a crucial role in medical treatments, particularly within the NIH's National Heart, Lung, and Blood Institute (NHLBI). Interested vendors should note that the primary contact for this opportunity is Brittany N. May, who can be reached at brittany.may@nih.gov or by phone at +1 301 594 4009 for further inquiries. Details regarding the funding amount and submission deadlines have not been specified in the provided information.
    Atropine and Pralidoxime Chloride, 'Duodote Kit"
    Buyer not available
    The Department of Health and Human Services, specifically the Office of the Assistant Secretary for Administration, is seeking quotes for the procurement of Atropine and Pralidoxime Chloride Autoinjectors, known as the "Duodote Kit." The requirement includes a total of 171 boxes, each containing 30 autoinjectors, to be delivered to the DHHS Receiving Dock located in Perry Point, Maryland. These autoinjectors are critical for emergency medical treatment, particularly in cases of organophosphate poisoning. Interested vendors should direct their inquiries to Tim Bouchelle at Timothy.Bouchelle@hhs.gov or by phone at 443-947-6039, with no set-aside restrictions applicable to this solicitation.